{
  "kind": "treatment",
  "slug": "eszopiclone-lunesta",
  "type": "hypnotic",
  "name": "Eszopiclone (Lunesta)",
  "summary": "A non-benzodiazepine hypnotic ('Z-drug') used for the treatment of insomnia.",
  "description": "Eszopiclone is a non-benzodiazepine hypnotic belonging to the cyclopyrrolone class, commonly referred to as a 'Z-drug.' It acts as a positive allosteric modulator of the GABA-A receptor at the benzodiazepine binding site, enhancing the inhibitory effect of GABA. It is indicated for the treatment of insomnia, including difficulty falling asleep and difficulty maintaining sleep.",
  "category": "medications/sleep-aids",
  "tags": [
    "hypnotic",
    "z-drug",
    "insomnia"
  ],
  "metadata": {
    "drug_classes": [
      "Non-benzodiazepine Hypnotic",
      "Sedative"
    ],
    "therapeutic_categories": [
      "Insomnia",
      "Sleep Disorders"
    ],
    "mechanism_categories": [
      "GABA"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": true,
    "generic_available": true,
    "brand_names": [
      "Lunesta"
    ],
    "dea_schedule": "CIV",
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term (with caution)"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Sleep Medicine",
      "Primary Care"
    ],
    "fda_approval_year": 2004
  },
  "clinical_metadata": {
    "primary_indications": [
      "Insomnia"
    ],
    "off_label_uses": [
      "Anxiety-related insomnia"
    ],
    "contraindications": [
      "Hypersensitivity to eszopiclone or any component",
      "History of complex sleep behaviors with hypnotics"
    ],
    "monitoring_required": [
      "Daytime sedation",
      "Complex sleep behaviors",
      "Signs of misuse or dependence"
    ],
    "efficacy_rating": {
      "insomnia": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "eszopiclone",
      "lunesta",
      "z-drug",
      "hypnotic"
    ],
    "synonyms": [
      "S-eszopiclone"
    ],
    "common_misspellings": [
      "eszoplicone",
      "lunesta"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Treatment of insomnia, including difficulty with sleep onset and/or sleep maintenance"
      ]
    },
    {
      "type": "mechanism",
      "text": "Acts as a positive allosteric modulator of the GABA-A receptor at the benzodiazepine site, enhancing the effects of GABA and promoting sleep."
    },
    {
      "type": "dosing",
      "adult": {
        "insomnia": "1–3 mg orally immediately before bedtime"
      },
      "geriatric": "Start at 1 mg; increase to 2 mg if needed",
      "hepatic_impairment": "Severe: max 2 mg nightly",
      "renal_impairment": "No adjustment needed"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 1 mg, 2 mg, 3 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset within 30 minutes; duration of action 6–8 hours."
    },
    {
      "type": "adverse_effects",
      "common": [
        "unpleasant taste",
        "dizziness",
        "drowsiness",
        "headache",
        "dry mouth"
      ],
      "less_common": [
        "hallucinations",
        "memory impairment",
        "depression"
      ],
      "serious": [
        "complex sleep behaviors",
        "severe allergic reactions",
        "dependence"
      ]
    },
    {
      "type": "warnings",
      "black_box": null,
      "other": [
        "Risk of complex sleep behaviors such as sleep-driving or sleep-eating",
        "May cause next-day impairment, especially at doses >2 mg",
        "Avoid alcohol and CNS depressants"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Alcohol",
          "risk": "Increased CNS depression",
          "action": "Avoid"
        },
        {
          "with": "Other CNS depressants",
          "risk": "Additive sedation",
          "action": "Use caution"
        },
        {
          "with": "CYP3A4 inhibitors",
          "risk": "Increased eszopiclone levels",
          "action": "Adjust dose"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Signs of next-day impairment",
        "Emergence of complex sleep behaviors",
        "Signs of dependence or misuse"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if benefits outweigh risks",
      "lactation": "Unknown excretion; use caution",
      "pediatrics": "Not approved for use in children",
      "geriatrics": "Start at lowest effective dose to avoid falls and confusion"
    },
    {
      "type": "tapering",
      "text": "Gradually reduce dose to avoid rebound insomnia or withdrawal symptoms."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Only Z-drug approved for long-term use in the U.S., but still use the lowest effective dose for the shortest duration",
        "Patients should allocate at least 7–8 hours for sleep after taking the dose",
        "Bitter or metallic taste is a common complaint"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Lunesta Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "American Academy of Sleep Medicine Guidelines",
          "url": "https://aasm.org/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Eszopiclone (Lunesta): Non-Benzodiazepine Hypnotic for Insomnia",
    "description": "Eszopiclone (Lunesta) is a non-benzodiazepine hypnotic ('Z-drug') used for the treatment of insomnia, improving sleep onset and maintenance."
  }
}
